Voglibose- Hypoglycemics -(FDC- List )- (Oct 1984)
Drug Name:Voglibose- Hypoglycemics -(FDC- List )- (Oct 1984)
List Of Brands:
Indication Type Description:
Drug Interaction
Indication
Adverse Reaction
Contra-Indications
Dosages/ Overdosage Etc
Pharmacology/ Pharmacokinetics
Interaction with Food
Drug Interaction:
Hypoglycemia may occur with co-administration of Voglibose with Insulin preparations or sulphonylurea derivatives. When administered concomittantly with drugs that enhance (beta blockers, salicylic acid preparations, mono amine oxidase inhibitors, fibrate derivatives ) or diminish (epinephrine, adrenocortical hormone, thyroid hormones etc. ) the hypoglycemc action of anti-diabetic drugs, caution should be taken, as it may delay the action of Voglinose.
Indication:
Adverse Reaction:
The gastrointestinal adverse events like diarrhea, abdominal pain, constipation, anorexia, nausea, vomiting or haert burn may occur with the use of Voglibose.
When Voglibose is administered to patients with serious liver cirrhosis, hyperammonia may worsen with the development of constipation.
When Voglibose is used in combination with antidiabetic drugs, hypoglycemia may occur.
Contra-Indications:
Patients with severe ketosis or in a state odf diabetic coma or pre-coma
Patients with severe infection before and after operation or with serious trauma
Patients with gastrointestinal obstruction or predisposed to it
Dosages/ Overdosage Etc:
The effects on blood sugar levels following meals will depend on the amount of complex carbohydrates in the meal.
Dosage-
0.2mg thrice daily May be increased to 0.3mg thrice daily To be taken just before meals
Pharmacology/ Pharmacokinetics:
Pharmacology-
Voglibose possesses a wide range of therapeutic activities and pharmacologic properties, including excellant inhibitory activity against Alpha -glucosidases and hyperglycemia. It has also shown anti-obesity and anti-diabetic activities. Vogilose is an Alpha glucosidase inhibitor which inhibits the activity of Alpha glucosidase enzymes, glucoamylase, sucrase that catalyze the decomposition of disaccharides into mono-saccharides in the intestine.
Thus it causes delay in digestion and absorption of carbhphydrates resulting in improved postprandal hyperglycemia. Viglibose upon oral adninistration slowly gets absorbed and excreted rapidly.
Clinical Efficacy- Alpha Glucosidase inhibitors may be used as monotherapy in patients predominently postprandial hyperglycemia
Interaction with Food:
Must be taken before meals to have maximal effect. The effects on blood sugar levels following meals will depend on the amount of complex carbohydrates in the meal.